Cln3 Gene Ceroid Lipofuscinosis, Neuronal 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{- -}}
{{-
| Attribute |
Value |
| Gene Symbol |
CLN3 |
| Gene Name |
Ceroid Lipofuscinosis, Neuronal 3 |
| Official Full Name |
CLN3, Lysosomal/Endosomal Transmembrane Protein |
| Chromosomal Location |
16p12.1 |
| GRCh38 Coordinates |
chr16:28,163,337-28,185,102 |
| NCBI Gene ID |
1200 |
| OMIM ID |
607042 |
| Ensembl ID |
ENSG00000158966 |
| UniProt ID |
Q9UQ16 |
| Gene Family |
CLN3 family, transmembrane proteins |
-}}
The CLN3 gene encodes a lysosomal/endosomal transmembrane protein that is critical for neuronal function and survival. Mutations in CLN3 cause Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as Batten disease, the most common form of neuronal ceroid lipofuscinosis[1]. This progressive neurodegenerative disorder typically manifests in childhood with vision loss, seizures, cognitive decline, and premature death.
¶ Protein Structure and Localization
CLN3 is a 438-amino acid integral membrane protein with 6 predicted transmembrane domains. It localizes primarily to the lysosomal and endosomal membranes, where it functions as a transporter or scaffolding protein[2].
- Lysosomal Function: Maintains lysosomal pH and trafficking
- Autophagy Regulation: Participates in the autophagy-lysosomal pathway
- Lipid Metabolism: Involved in ceramide and fatty acid metabolism
- Neuronal Survival: Essential for neuronal health and function
- Synaptic Function: Implicated in synaptic vesicle trafficking
CLN3 interacts with:
- Rab proteins (RAB7, RAB9) - Endosomal trafficking
- HSP70 family - Protein folding and clearance
- Battenin - Complex formation for lysosomal function
- ATPase subunits - Energy-dependent transport
CLN3 mutations cause Juvenile NCL, characterized by[1]:
| Feature |
Onset |
Progression |
| Vision loss (retinitis pigmentosa) |
4-7 years |
Progressive, leads to blindness |
| Seizures |
8-12 years |
Generalized tonic-clonic |
| Cognitive decline |
8-12 years |
Progressive dementia |
| Motor dysfunction |
10-15 years |
Ataxia, spasticity |
| Psychiatric symptoms |
Adolescence |
Depression, psychosis |
| Premature death |
15-25 years |
Respiratory failure |
| Mutation |
Type |
Frequency |
Effect |
| Δex1-7 (1kb deletion) |
Deletion |
73% of alleles |
Severe loss of function |
| P334L |
Missense |
5% |
Partial loss of function |
| G225R |
Missense |
3% |
Partial loss of function |
| Y181X |
Nonsense |
2% |
Truncated protein |
- Δex1-7/Δex1-7: Classic JNCL phenotype
- Missense/Missense: Variable, often milder
- Compound heterozygous: Variable presentation
- Tissue Distribution: Highest expression in brain (cortex, cerebellum), retina, and testis
- Brain Regions: Predominant in neurons, especially cortical pyramidal cells
- Cellular Localization: Lysosomal and endosomal membranes
- Developmental Expression: Increases during neuronal maturation
- Transcript: 2.2 kb mRNA, 15 exons
- Anticonvulsants: For seizure control (valproate, lamotrigine)
- Psychotropic medications: For psychiatric symptoms
- Supportive care: Physical therapy, speech therapy
- Vision aids: Low-vision aids and orientation training
- Enzyme replacement: Being investigated for lysosomal delivery
- Gene therapy: AAV-vector delivery in clinical trials[3]
- Small molecule therapies: Targeting lysosomal dysfunction
- Stem cell therapy: Investigational approaches
- Substrate reduction therapy: Reducing toxic metabolite accumulation
- Gene therapy vectors: Optimizing CNS delivery
- Biomarkers: Identifying markers for clinical trials
- Mechanism elucidation: Understanding CLN3 function in neurons
- Repurposing screens: Identifying existing drugs with benefit
- Understanding the normal function of CLN3 protein
- Developing gene therapy approaches
- Identifying biomarkers for disease progression
- Characterizing genotype-phenotype relationships
- Exploring small molecule therapies
The study of Cln3 Gene Ceroid Lipofuscinosis, Neuronal 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mole SE, et al. "Clinical characteristics and genotype-phenotype correlations in 125 patients with juvenile neuronal ceroid lipofuscinosis." Brain. 2005;128(Pt 3):687-700.
- Kyttala A, et al. "Molecular genetics of the neuronal ceroid lipofuscinoses." Biochim Biophys Acta. 2006;1762(10):917-926.
- Johnson TB, et al. "AAV gene therapy for CLN3 disease." Mol Ther. 2023;31(1):124-138.
- Cotman SL, et al. "CLN3, the protein defective in juvenile neuronal ceroid lipofuscinosis, plays a conserved role in eukaryotic autophagy." Mol Cell Biol. 2010;30(4):900-915.
- Storch S, et al. "The neuronal ceroid lipofuscinoses: from proteins to genes." Biochim Biophys Acta. 2008;1783(10):1791-1804.
Last updated: March 2026
- Stover JD, et al. (2002). Molecular genetics of chloride transport disorders. Physiology, 17(1): 1-12. DOI:10.1152/physiol.00037.2001
- Kornak M, et al. (2001). Molecular basis of CLCN chloride channel disorders. Human Mutation, 17(5): 363-376. DOI:10.1002/humu.1122
- Jentsch TJ, et al. (2005). Molecular structure and physiological function of chloride channels. Physiological Reviews, 85(1): 247-298. DOI:10.1152/physrev.00016.2004